Pharmacogenomics: application to the management of cardiovascular disease
journal contributionposted on 2012-06-25, 00:00 authored by Julie A. Johnson, Larisa H. Cavallari, Amber L. Beitelshees, Joshua P. Lewis, Alan R Shuldiner, Dan M. Roden
There have been substantial advances in cardiovascular pharmacogenomics in the past decade. Genetic determinants of response to clopidogrel and warfarin have been defined, resulting in changes to the product label for each drug that suggests use of genetic information to guide therapy. Genetic tests are available, as are guidelines for incorporation of genetic information into patient care decisions. These guidelines and literature supporting them are reviewed. Significant advances have also been made in the pharmacogenomics of statininduced myopathy, and response to beta-blockers in heart failure, although the clinical applications of these findings are less clear. Other areas hold promise, including pharmacogenomics of antihypertensive drugs, aspirin, and drug-induced long QT syndrome. The potential value of pharmacogenomics in new drug discovery and drug development is also described. In summary, pharmacogenomics has current applications in management of cardiovascular disease, with clinically-relevant data continuing to mount.
Supported in part by grants from the NIH Pharmacogenomics Research Network – U01 GM074492 (JAJ), U19 HL065962 (DMR), U01 HL105198 (ARS); K23 HL091120 (ALB); AHA 10GRNT3750024 (LHC)
Publisher StatementPost print version of article may differ from published version. The definitive version is available through Nature Publishing Group at doi:10.1038/clpt.2011.179
PublisherNature Publishing Group